Northland Capmk Brokers Increase Earnings Estimates for TLSI

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Research analysts at Northland Capmk raised their FY2026 EPS estimates for TriSalus Life Sciences in a report released on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of ($0.60) for the year, up from their previous forecast of ($0.75). Northland Capmk has a "Strong-Buy" rating on the stock. The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share.

A number of other equities analysts also recently commented on TLSI. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an "outperform" rating and a $10.00 target price for the company. Roth Capital raised TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday, November 11th. Northland Securities began coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an "outperform" rating and a $12.50 target price on the stock. Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Finally, Roth Mkm assumed coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They issued a "buy" rating and a $11.00 price target on the stock. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $12.08.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI traded down $0.07 during trading hours on Thursday, reaching $4.25. The stock had a trading volume of 234,458 shares, compared to its average volume of 39,429. TriSalus Life Sciences has a 1 year low of $3.61 and a 1 year high of $10.42. The firm's 50 day moving average is $4.22 and its 200-day moving average is $5.47. The stock has a market capitalization of $129.58 million, a price-to-earnings ratio of -1.71 and a beta of 0.49.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Duquesne Family Office LLC raised its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after buying an additional 110,966 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at approximately $1,184,000. Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after acquiring an additional 62,542 shares during the last quarter. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $240,000. Finally, MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $184,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of the business's stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the acquisition, the chief executive officer now directly owns 377,382 shares of the company's stock, valued at $1,962,386.40. The trade was a 2.03 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought a total of 19,560 shares of company stock valued at $95,190 in the last three months. 32.80% of the stock is currently owned by company insiders.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.